Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 201–300 of 1,733
Testosterone Deficiency and Risk of Cognitive Disorders in Aging Males
Corona, G., Guaraldi, F., Rastrelli, G., Sforza, A., & Maggi, M. (2020) · The World Journal of Men s Health · doi:10.5534/wjmh.200017 · Cited by 44
“In addition, the use of FTI for the assessment of androgen status has been strongly criticized [45].”
Dwyer, A. A., Chavan, N. R., Lewkowitz-Shpuntoff, H., Plummer, L., Hayes, F. J., Seminara, S. B., Crowley, W. F., Pitteloud, N., & Balasubramanian, R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02697 · Cited by 41
“4 nmol/L) (threshold consistent with current Endocrine Society guidelines for testosterone therapy in men with hypogonadism) (23), accompanied by symptoms of hypogonadism (i.”
BackgroundSelf-citationMorbidity in Klinefelter syndrome and the effect of testosterone treatment
Chang, S., Skakkebaek, A. H., Davis, S., & Gravholt, C. H. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31798 · Cited by 49
“…as how to treat this specific patient group, when to start treatment, which route to use when choosing testosterone supplementation, which dose to use, which target tissues to monitor, how often to monitor, or which treatment goals to use to declare treatment a success or not (Bhasin et al., 2018).”
BackgroundInfluentialLate‐onset hypogonadism and lifestyle‐related metabolic disorders
Braga, P. C., Pereira, S., Ribeiro, J. C., Sousa, M., Monteiro, M. P., Oliveira, P. F., & Alves, M. G. (2020) · Andrology · doi:10.1111/andr.12765 · Cited by 46
Lerchbaum, E., Trummer, C., Theiler-Schwetz, V., Kollmann, M., Wölfler, M., Heijboer, A. C., Pilz, S., & Obermayer-Pietsch, B. (2019) · European Journal of Nutrition · doi:10.1007/s00394-018-1858-z · Cited by 40
Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option
Figueiredo, M. G., Gagliano‐Jucá, T., & Basaria, S. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab772 · Cited by 44
Swee, D. S., & Quinton, R. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819826889 · Cited by 45
Type 2 Diabetes and Testosterone Therapy
Hackett, G. I. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.180027 · Cited by 48
Awouters, M., Vanderschueren, D., & Antonio, L. (2020) · Andrology · doi:10.1111/andr.12725 · Cited by 39
Gagliano‐Jucá, T., Pencina, K. M., Guo, W., Li, Z., Huang, G. T.-W., Basaria, S. S., & Bhasin, S. (2020) · Andrology · doi:10.1111/andr.12834 · Cited by 45
Self-citationLeisegang, K., Roychoudhury, S., Sláma, P., & Finelli, R. (2021) · Antioxidants · doi:10.3390/antiox10111834 · Cited by 45
“TRT is contraindicated in prostate carcinoma, benign prostate hyperplasia, increased prostate-specific antigens, and a history of cardiovascular events [3,96].”
BackgroundSchooling, C., Zhao, J., Au Yeung, S., & Leung, G. (2020) · eLife · doi:10.7554/elife.58567 · Cited by 39
“The Endocrine Society has also recommended caution in the use of testosterone (Bhasin et al., 2018).”
BackgroundRoşca, A. E., Vlădăreanu, A., Mititelu, A., Popescu, B. O., Badiu, C., Căruntu, C., Voiculescu, S. E., Onisâi, M., Gologan, S., Mirică, R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010147 · Cited by 42
“For instance, considering a parenteral dose of testosterone enanthate or cypionate of 150–200 mg every two week in men with hypogonadism [13], the aforementioned abus dose is 6 to 500 times higher than that recommended in testosterone replacement therapy.”
BackgroundFode, M. M., Salonia, A., Minhas, S., Burnett, A. L. “., & Shindel, A. W. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.021 · Cited by 38
“Total T testing is indicated in the presence of symptoms and/or conditions known to be associated with LOH (Table 2) [7], but not in routine screening [7].”
BackgroundMushannen, T., Cortez, P., Stanford, F. C., & Singhal, V. (2019) · Children · doi:10.3390/children6050063 · Cited by 50
“In addition, treatment has also been seen to improve areal and volumetric bone mineral density and bone strength in the hip and spine in older men with hypogonadism [116].”
BackgroundLongitudinal Changes in Hematologic Parameters Among Transgender People Receiving Hormone Therapy
Antun, A. G., Zhang, Q., Bhasin, S., Bradlyn, A. S., Flanders, W. D., Getahun, D., Lash, T. L., Nash, R., Roblin, D. W., Silverberg, M. J., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa119 · Cited by 48
“According to the Endocrine Society guidelines, clinically significant testosterone-induced erythrocytosis can be treated with therapeutic phlebotomy; however, there is no clear Hct cutoff above which therapeutic phlebotomy is clearly indicated [36].”
BackgroundSelf-citationTrends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014
Zhou, C. K., Advani, S., Chaloux, M., Gibson, J. T., Yu, M., Bradley, M. C., Hoover, R. N., & Cook, M. B. (2020) · The Journal of Urology · doi:10.1097/ju.0000000000000744 · Cited by 39
INSL3: A Marker of Leydig Cell Function and Testis-Bone-Skeletal Muscle Network
Facondo, P., Delbarba, A., Maffezzoni, F., Cappelli, C., & Ferlin, A. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527666200925105739 · Cited by 40
Chasland, L. C., Yeap, B. B., Maiorana, A., Chan, Y. X., Maslen, B. A., Cooke, B. R., Dembo, L. G., Naylor, L. H., & GREEN, D. J. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00010.2021 · Cited by 46
Cignarelli, A., Castellana, M., Castellana, G., Perrini, S., Brescia, F., Natalicchio, A., Garruti, G., Laviola, L., Resta, O., & Giorgino, F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00551 · Cited by 37
“Among the causes of functional hypogonadism, sleep disorders are listed (11).”
BackgroundMethodInfluentialSex differences in childhood sleep and health implications
Smidt, S. D. E., Hitt, T. A., Zemel, B. S., & Mitchell, J. A. (2021) · Annals of Human Biology · doi:10.1080/03014460.2021.1998624 · Cited by 37
“With respect to testosterone impacting sleep, there is some evidence from testosterone replacement studies for men with hypogonadism that such therapy at normal doses can worsen obstructive sleep apnoea (OSA) and at supraphysiologic doses can shorten sleep duration and sleep efficiency (Liu et al. 2003; Bhasin et al.…”
BackgroundAgana, M. G., Greydanus, D. E., Indyk, J. A., Calles, J. L., Kushner, J., Leibowitz, S. F., Chelvakumar, G., & Cabral, M. D. (2019) · Disease-a-Month · doi:10.1016/j.disamonth.2019.07.004 · Cited by 60
Falqueto, H., Júnior, J. L. R., Silvério, M. N. O., Farias, J. C. H., Schoenfeld, B. J., & Manfredi, L. H. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09634-4 · Cited by 48
Yeap, B. B., Marriott, R. J., Antonio, L., Bhasin, S., Dobs, A. S., Dwivedi, G., Flicker, L. A., Matsumoto, A. M., Ohlsson, C., ORWOLL, E. S., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14342 · Cited by 38
Self-citationVartolomei, M. D., Kimura, S., Vartolomei, L., & Shariat, S. F. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.07.006 · Cited by 40
Effects of endocrine disorders on lipids and lipoproteins
Newman, C. B. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101667 · Cited by 40
La Vignera, S., Cannarella, R., Galvano, F., Grillo, A., Aversa, A., Cimino, L., Magagnini, C. M., Mongioì, L. M., Condorelli, R. A., & Calogero, A. E. (2021) · Endocrine · doi:10.1007/s12020-020-02518-8 · Cited by 36
Sexual Dysfunction in Men Who Have Sex With Men
Cheng, P. J. (2021) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2021.01.002 · Cited by 47
Advances in stem cell research for the treatment of primary hypogonadism
Li, L., & Papadopoulos, V. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00480-2 · Cited by 41
van der Veen, A., van Faassen, M. H. J. R., de Jong, W. H. A., van Beek, A. P., Dijck-Brouwer, J., & Kema, I. P. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.03.013 · Cited by 38
Oakes, M., Arastu, A., Kato, C. M., Somers, J., Holly, H. D., Elstrott, B. K., Dy, G. W., Kohs, T. C. L., Patel, R. R., McCarty, O. J. T., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.09.005 · Cited by 41
The CATCH checklist to investigate adult‐onset hypogonadism
Defeudis, G., Mazzilli, R., Gianfrilli, D., Lenzi, A., & Isidori, A. M. (2018) · Andrology · doi:10.1111/andr.12506 · Cited by 38
“In the recent Endocrine Society Clinical Practice Guidelines (Bhasin et al., 2018), the authors suggested no routinely replacement treatment to all men over 65 years aged; furthermore, an individualized therapy is suggested, after an explanation of the potential benefits and the possible risks with the patient.”
BackgroundMethodInfluentialBhasin, S., Krishnan, V., Storer, T. W., Steiner, M., & Dobs, A. S. (2023) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glad027 · Cited by 36
Self-citationTestosterone in males with COVID‐19: a 12‐month cohort study
Salonia, A., Pontillo, M., Capogrosso, P., Pozzi, E., Ferrara, A. M., Cotellessa, A., Belladelli, F., Corsini, C., Gregori, S., Rowe, I., et al. (2022) · Andrology · doi:10.1111/andr.13322 · Cited by 36
Estrada-Almeida, A. G., Castrejón-Godínez, M. L., Mussali-Galante, P., Tovar‐Sánchez, E., & Rodríguez, A. (2024) · Journal of Xenobiotics · doi:10.3390/jox14040082 · Cited by 49
Erectile dysfunction as a marker of endocrine and glycemic disorders
Mazzilli, R., Zamponi, V., Olana, S., Mikovic, N., Cimadomo, D., Defeudis, G., & Faggiano, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01788-5 · Cited by 52
“5 ng/dl [18]; (2) hyperprolactinemia: prolactin levels > 25 ng/ml, measured after a rest of at least 20 min after insertion of a cannula; (3) overt thyroid hyperthyroidism or hypothyroidism: TSH < 0.”
BackgroundKumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., et al. (2023) · Clinics and Practice · doi:10.3390/clinpract13020041 · Cited by 36
“as well as the presence of hypogonadism symptoms [1].”
BackgroundDavid, K., Narinx, N., Antonio, L., Evenepoel, P., Claessens, F., Decallonne, B., & Vanderschueren, D. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09738-5 · Cited by 41
Grinspon, R. P., Urrutia, M., & Rey, R. A. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.67 · Cited by 44
“When full pubertal development is attained, treatment should be switched to follow standards for adults.(1) Alternative approaches include oral androgens such as testosterone undecanoate(40) and transdermal gels.”
BackgroundMethodOpioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis
Wehbeh, L., & Dobs, A. S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa417 · Cited by 39
Maggi, M., Rastrelli, G., & Corona, G. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_61_19 · Cited by 36
Oral glucose load and mixed meal feeding lowers testosterone levels in healthy eugonadal men
Gagliano‐Jucá, T., Li, Z., Pencina, K. M., Beleva, Y. M., Carlson, O. D., Egan, J. M., & Basaria, S. S. (2018) · Endocrine · doi:10.1007/s12020-018-1741-y · Cited by 36
Impaired ketogenesis in Leydig Cells drives testicular aging
Liu, C., Peng, H. Y., Yu, J., Luo, P., Xiong, C., Chen, H., Fan, H., Ma, Y., Ou, W., Zhang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59591-8 · Cited by 45
“Considering the potential health risks associated with exogenous testosterone replacement therapy 7 – 10 , the use of ketone body supplementation offers a viable and promising alternative for counteracting testicular aging.”
Collet, T., Ewing, S. K., Ensrud, K. E., Laughlin, G. A., Hoffman, A. R., Varosy, P. D., Stefanick, M. L., Stone, K. L., ORWOLL, E. S., & Bauer, D. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa038 · Cited by 35
“As highlighted by the recently updated Endocrine Society guidelines on T replacement therapy [26], clinicians should be wary of potential cardiovascular complications of exogenous T in older men.”
BackgroundMethodInfluentialThe Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism
Shin, Y. S., & Park, J. K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020209 · Cited by 37
“Given that the direct method for FT measurement is also time consuming and labor intensive, recent guidelines do not recommend using FT measurements as the primary diagnostic method for LOH [13,15,18,30].”
BackgroundMethodInfluentialOni, O. A., Dehkordi, S. H. H., Jazayeri, M., Sharma, R., Sharma, M., Masoomi, R., Sharma, R., Gupta, K., & Barua, R. S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.07.019 · Cited by 36
Best, C. M., Pressman, E. K., Queenan, R. A., Cooper, E., & O'Brien, K. O. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.09.019 · Cited by 35
“For thyroid hormones and testosterone, the free hormone concentration is routinely used in clinical care [2, 3], and it is particularly relevant in patients with altered levels of hormone binding proteins [4, 5].”
BackgroundGagliano‐Jucá, T., Pencina, K. M., Ganz, T., Travison, T. G., Kantoff, P. W., Nguyen, P. L., Taplin, M., Kibel, A. S., Li, Z., Huang, G. T.-W., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00272.2018 · Cited by 34
“301 Hepcidin, ng/ml 17 (12; 22) 1 ( 6; 4) 18 (10; 25) <0.”
BackgroundIrwig, M. S., Fleseriu, M., Jonklaas, J., Tritos, N. A., Yuen, K. C. J., Correa, R. R., Elhomsy, G. C., Garla, V. V., Jasim, S., Soe, K. K., et al. (2020) · Endocrine Practice · doi:10.4158/ps-2019-0540 · Cited by 41
“Clinical practice guidelines are also available for clinicians on the diagnosis and treatment of androgen deficiency, GH deficiency, hypothyroidism, and adrenal insufficiency (10,23,49,50,122).”
BackgroundInfluentialFrom liver to hormones: The endocrine consequences of cirrhosis
Aldave, J. E. Q., Osorio, E. R. G., Durand‐Vásquez, M. D. C., Rafael-Robles, L. D. P., Yovera, J. G. G., Quispe-Flores, M. A., Urteaga, L. A. C., Román-Gonzaléz, A., Paz‐Ibarra, J., & Concepción‐Zavaleta, M. J. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i9.1073 · Cited by 45
Gender Differences in Response to COVID-19 Infection and Vaccination
Zaher, K. A., Basingab, F. S., Alrahimi, J., Basahel, K., & Aldahlawi, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061677 · Cited by 48
“IL-6, TNF-, and IL-1 are also greater in older men with reduced testosterone [85].”
BackgroundTestosterone Supplementation and Cognitive Functioning in Men—A Systematic Review and Meta-Analysis
Buskbjerg, C. R., Gravholt, C. H., Dalby, H. R., Amidi, A., & Zachariae, R. H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00119 · Cited by 38
“This approach has several drawbacks, given that reported ranges for testosterone concentrations vary among laboratories and assays and that testosterone levels should not be evaluated in isolation without taking important confounding factors, such as sexual hormone-binding globulin levels, into account [64].”
BackgroundStephens‐Shields, A. J., Snyder, P. J., Ellenberg, S. S., Taylor, L., & Bhasin, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac028 · Cited by 37
Self-citationMetabolic syndrome and erectile dysfunction: a systematic review and meta-analysis study
Corona, G., Vena, W., Pizzocaro, A., Rastrelli, G., Sparano, C., Sforza, A., Vignozzi, L., & Maggi, M. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02136-x · Cited by 48
“A large body of evidence has shown that T replacement therapy (TRT) can ameliorate all aspects of erectile function in hypogonadal subjects [47, 48, 69, 70].”
Correlation Between Gut Microbiota and Testosterone in Male Patients With Type 2 Diabetes Mellitus
Liu, S., Cao, R., Liu, L., Lv, Y., Qi, X., Yuan, Z., Fan, X., Yu, C., & Guan, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836485 · Cited by 42
Amory, J. K., Blithe, D., Sitruk-Ware, R. L., Swerdloff, R. S., Bremner, W. J., Dart, C., Liu, P. Y., Thirumalai, A., Nguyen, B. T., Anawalt, B. D., et al. (2023) · Contraception · doi:10.1016/j.contraception.2023.110064 · Cited by 34
Self-citationSafety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Gittelman, M., Jaffe, J., & Kaminetsky, J. (2019) · Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.08.013 · Cited by 28
New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism
Spaziani, M., Carlomagno, F., Tarantino, C., Angelini, F., Vincenzi, L., & Gianfrilli, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1184530 · Cited by 41
“In addition, TRT should be administered in HIV patients with reduced body weight and low testosterone levels, in order to maintain weight and lean mass, with an overall improvement in quality of life (36).”
BackgroundYeo, S., Holl, K., Peñaherrera, N., Wissinger, U., Anstee, K., & Wyn, R. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s285434 · Cited by 39
Antonič, K. G., Antonič, B., Žuran, I., & Pfeifer, M. (2020) · The Aging Male · doi:10.1080/13685538.2020.1793132 · Cited by 33
“Inclusion and exclusion criteria were reviewed at screening visit where patients were asked about symptoms and signs suggestive of hypogonadism in accordance with the clinical practice guidelines [6,39], underwent clinical history and physical examination.”
BackgroundMethodGuideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms
Dubin, J. M., Jesse, E., Fantus, R. J., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.4928 · Cited by 32
Hypogonadism and bone health in men with HIV
Maffezzoni, F., Porcelli, T., Delbarba, A., Pezzaioli, L. C., Properzi, M., Cappelli, C., Castelli, F., Quiros-Roldan, M. E., & Ferlin, A. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30236-8 · Cited by 37
Anand‐Ivell, R., Heng, K., Severn, K. E., Antonio, L., Bártfai, G., Casanueva, F. F., Huhtaniemi, I. T., Giwercman, A., Maggi, M., O’Neill, T. W., et al. (2022) · Andrology · doi:10.1111/andr.13220 · Cited by 32
“Alcohol consumptionwas provided in terms of approximatelyweekly intake, whereby formultivariate analysis, 0–1 alcoholic drinks perweekwere allocated “low” (0), 2–4 drinks perweek “moderate” (1), and>4 drinks per week “high” (2).”
MethodSelf-citationSesti, F. F., Pofi, R., Minnetti, M., Tenuta, M., Gianfrilli, D., & Isidori, A. M. (2020) · Andrology · doi:10.1111/andr.12876 · Cited by 33
Salvio, G., Ciarloni, A., Ambo, N., Bordoni, M., Perrone, M., Rossi, S., & Balercia, G. (2025) · Andrology · doi:10.1111/andr.70022 · Cited by 41
Xia, K., Wang, F., Lai, X., Dong, L., Luo, P., Zhang, S., Yang, C., Chen, H., Ma, Y., Huang, W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100792 · Cited by 41
Zitzmann, M., & Rohayem, J. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31786 · Cited by 40
“Diagnosis, treatment, and surveillance of hypogonadism in adults should follow the respective general guidelines (Bhasin et al., 2018; Mirone et al., 2017; Salonia et al., 2019).”
BackgroundHormonal Therapies in Multiple Sclerosis: a Review of Clinical Data
Hsu, S., & Bove, R. M. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01326-7 · Cited by 36
“To summarize these findings, to date, testosterone therapy can be considered in individuals with MS with clinical hypog-onadism and according to current clinical guidance of the general population linked to the Endocrine Society [56].”
MethodMetabolic and Endocrine Toxicities of Mitotane: A Systematic Review
Bianchini, M., Puliani, G., Chiefari, A., Mormando, M., Lauretta, R., & Appetecchia, M. (2021) · Cancers · doi:10.3390/cancers13195001 · Cited by 38
“taneous erections, and erectile dysfunction [70,71].”
BackgroundAdorni, M. P., Zimetti, F., Cangiano, B., Vezzoli, V., Bernini, F., Caruso, D., Corsini, A., Sirtori, C. R., Cariboni, A. M., Bonomi, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02027 · Cited by 33
Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
French, D. (2023) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2023.01.006 · Cited by 33
Hackett, G. I., Cole, N., Mulay, A., Strange, R. C., & Ramachandran, S. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.180052m · Cited by 31
“Similarly, some studies have shown reduction in inflammatory markers with others showing little or no change [13,15].”
BackgroundResultGuardo, F. D., Vloeberghs, V., Bardhi, E., Blockeel, C., Verheyen, G., Tournaye, H. J., & Drakopoulos, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123824 · Cited by 40
“Our study included only asymptomatic men who provided an early morning blood sample (before 10 a.m.), as recommended by the Endocrine Society guidelines in order to avoid the natural diurnal variation in blood serum testosterone levels [15], and none had been on exogenous testosterone or other relevant medication such…”
BackgroundResultInfluentialBarros, P. R., Costa, T. J. D., Akamine, E. H., & Tostes, R. C. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.727604 · Cited by 34
Furini, C., Spaggiari, G., Simoni, M., Greco, C., & Santi, D. (2022) · Endocrine · doi:10.1007/s12020-022-03195-5 · Cited by 32
Sheng, J. A., Tan, S. M. L., Hale, T. M., & Handa, R. J. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0021 · Cited by 39
“those who received TRT in contrast to the placebo group, implicating the role of T in attenuating depressive- and anxiety-like symptoms.(152) Such effects of T treatment are further demonstrated in animal”
Aversa, A., Duca, Y., Condorelli, R. A., Calogero, A. E., & Vignera, S. L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00225 · Cited by 35
Kumar, S., Khatri, M., Memon, R. A., Llerena-Velastegui, J., Zumbana-Podaneva, K., Benitez-Gutierrez, D., Nadeem, B., Anumolu, A. R., Azhar, M., & Zain, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102588 · Cited by 30
Hypothalamic–Pituitary Diseases and Erectile Dysfunction
Salvio, G., Martino, M., Giancola, G., Arnaldi, G., & Balercia, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122551 · Cited by 41
“The latter condition is present when T levels are low and gonadotropin levels are low or inappropriately normal [12].”
BackgroundEMAS position statement: Testosterone replacement therapy in older men
Kanakis, G., Pofi, R., Goulis, D. G., Isidori, A. M., Armeni, E., Erel, C. T., Fistonić, I., Hillard, T., Hirschberg, A. L., Męczekalski, B., et al. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107854 · Cited by 40
“Reduced T concentrations can affect bone health in terms of mass and strength [74] as well as bone mineral density (BMD), and represent a major risk factor for osteoporosis [71,72,74,75]; nevertheless, the effects of TRT on bone homeostasis in ageing men with LOH are conflicting [73,76].”
BackgroundPozzi, E., Boeri, L., Candela, L., Capogrosso, P., Cazzaniga, W., Fallara, G., Cignoli, D., Belladelli, F., Cornelius, J., Abbate, C., et al. (2021) · Andrology · doi:10.1111/andr.13071 · Cited by 34
Testosterone deficiency and chronic kidney disease
Zitzmann, M. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100365 · Cited by 61
“Additionally, physical injuries to the testes disrupt testosterone synthesis [2].”
BackgroundInfluentialRebello, E., Albright, J. A., Testa, E. J., Alsoof, D., Daniels, A. H., & Arcand, M. A. (2023) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2023.02.122 · Cited by 30
Pellikaan, K., Brahim, Y. B., Rosenberg, A. G. W., Davidse, K., Poitou, C., Coupaye, M., Goldstone, A. P., Höybye, C., Markovic, T., Grugni, G., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194361 · Cited by 33
Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male
Scovell, J. M., & Khera, M. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.07.033 · Cited by 32
Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review
Liu, J., Chin-Yee, B. H., Ho, J., Lazo‐Langner, A., Chin-Yee, I. H., Iansavitchene, A., & Hsia, C. C. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015410 · Cited by 35
“40,27,41,35 This is similar to current Endocrine Society clinical practice guidelines 14 on testosterone therapy in males with hypogonadism, which recommends temporarily holding testosterone if hematocrit levels exceed 54% and resuming therapy at a lower dose once hematocrit normalizes; phlebotomy…”
Transgender healthcare: metabolic outcomes and cardiovascular risk
Glintborg, D., Christensen, L. L., & Andersen, M. (2024) · Diabetologia · doi:10.1007/s00125-024-06212-6 · Cited by 36
Cunningham, G. R., Ellenberg, S. S., Bhasin, S., Matsumoto, A. M., Parsons, J. K., Preston, P. E., Cauley, J. A., Gill, T. M., Swerdloff, R. S., Wang, C., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00806 · Cited by 30
Self-citationJasuja, G. K., Ameli, O., Reisman, J. I., Rose, A. J., Miller, D. R., Berlowitz, D. R., & Bhasin, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17141 · Cited by 30
Self-citationAnabolic steroid excess and myocardial infarction: From ischemia to reperfusion injury
Seara, F. D. A. C., Olivares, E. L., & Nascimento, J. H. M. (2020) · Steroids · doi:10.1016/j.steroids.2020.108660 · Cited by 34
Short-Acting Testosterone: More Physiologic?
Westfield, G., Kaiser, U. B., Lamb, D. J., & Ramasamy, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572465 · Cited by 28
Endosialin defines human stem Leydig cells with regenerative potential
Xia, K., Ma, Y., Feng, X. G., Deng, R., Ke, Q., Xiang, A. P., & Deng, C. (2020) · Human Reproduction · doi:10.1093/humrep/deaa174 · Cited by 31
“Administration of exogenous testosterone, known as testosterone replacement therapy, is the most widely used treatment for hypogonadism, and it can help to reverse many of the symptoms caused by low testosterone levels (Bhasin et al. , 2018).”
Testosterone improves muscle fiber asset and exercise performance in a metabolic syndrome model
Sarchielli, E., Comeglio, P., Filippi, S., Cellai, I., Guarnieri, G., Guasti, D., Rapizzi, E., Rastrelli, G., Bani, D., Vannelli, G. B., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0532 · Cited by 27
Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update
Romigi, A., Feola, T., Cappellano, S., De Angelis, M., Pio, G., Caccamo, M., Testa, F., Vitrani, G., Centonze, D., Colonnese, C., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.817257 · Cited by 28
Approach to Obesity in the Older Population
Buch, A., Marcus, Y., Shefer, G., Zimmet, P., & Stern, N. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab359 · Cited by 32
Nolan, B. J., Leemaqz, S., Ooi, O., Cundill, P., Silberstein, N., Locke, P., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2021) · Internal Medicine Journal · doi:10.1111/imj.14839 · Cited by 30
Testosterone Treatment of Depressive Disorders in Men
Bhasin, S., & Seidman, S. N. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2661 · Cited by 28
Self-citationWalsh, J., Marshall, H. C., Smith, I. L., Greenfield, D., Swain, J., Best, E. L., Ashton, J., Brown, J. M., Huddart, R. A., Coleman, R. E., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002960 · Cited by 29
“The Endocrine Society guidelines recommend that the diagnosis of testosterone deficiency is only made in men with consistent symptoms and signs and a clearly low serum testosterone [9].”
BackgroundInfluentialAgeing male (part I): Pathophysiology and diagnosis of functional hypogonadism
Huhtaniemi, I. T., & Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101622 · Cited by 31
Self-citationEffects of testosterone treatment on clitoral haemodynamics in women with sexual dysfunction
Cipriani, S., Maseroli, E., Stasi, V. D., Scavello, I., Todisco, T., Rastrelli, G., Fambrini, M., Sorbi, F., Petraglia, F., Jannini, E. A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01598-1 · Cited by 31
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.